nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

10.04.2017 | Review Article

The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed

verfasst von: Jorge Hernando-Cubero, Ignacio Matos-García, Vicente Alonso-Orduña, Jaume Capdevila

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastrointestinal tumours are one of the most common types of cancer. Therapeutic options include surgery, radiotherapy, local ablation techniques, targeted agents, and chemotherapy. Fluoroprimidines are one of the most active drug families in digestive tumours and remains the cornerstone of the most commonly used chemotherapy schemes.

Methods

We review the molecular basis of thymidylate synthase inhibition and the mechanisms of action of 5-fluorouracil, next generation oral fluoropyrimidines (capecitabine, tegafur and the latest S-1 and TAS-102) and antifolates.

Results

In addition, mechanisms and biomarkers of resistance and toxicity are explored. Finally, new fluoropyrimidines development and clinical trials ongoing in digestive tumours are reviewed.

Conclusions

Further research is necessary to avoid resistance mechanisms, improve clinical outcomes and continue reducing toxicities. Until new drugs become available, the optimization of current therapies should be a priority.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRef

Stoehlmacher J. Prediction of efficacy and side effects of chemotherapy in colorectal cancer. Recent Results Cancer Res. 2007;176:81–8.PubMedCrossRef

Di Francia R, Siesto RS, Valente D, et al. Pharmacogenomics panel test for prevention toxicity in patient who receive fluoropirmidine/oxaliplatin-based therapy. Eur Rev Pharmacol Sci. 2012;16(9):1211–7.

Tol J, Punt CJ. Monoclonal antiboides in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32(3):437–53.PubMedCrossRef

Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews. 2014;11:282–98.PubMed

Goulian M, Bleile BM, Dickey LM, et al. Mechanisms of thymineless death. Adv Exp Med Biol. 1986;195B:89–95.CrossRef

Brynolf K, Eliasson R, Reichard P. Formation of Okazaki fragments in polyoma DNA synthesis caused by misincorporation of uracil. Cell. 1978;13:573–80.PubMedCrossRef

Heidelberg C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–6.CrossRef

Jaffe JJ, Handschumacher RE, Welch AD. Studies of the carcinostatic activity in mice of 6-azauracil riboside (azauridine), incomparison with that of 6-azauracil. Yale J Biol Med. 1957;30:168–75.PubMedPubMedCentral

10.

Sobrero A, Guglieimi A, Grossi F, et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cáncer chemotherapy. Semin Oncol. 2000;27(10):72–7.PubMed

11.

Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer—a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997;15(1):368–81.PubMedCrossRef

12.

Houghton JA, Maroda SJ, Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 1981;41:144–49

13.

The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Jour Clin Oncol. 2004;22(18):3766–75.CrossRef

14.

Ardalan B, Luis R, Jaime M, et al. Biomodulation of fluorouracil in colorectal cáncer. Cancer Investig. 1998;16(4):237–51.CrossRef

15.

Mullany S, Svingen PA, Kaufmann SH, et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 1998;42:391–9.PubMedCrossRef

16.

Cao S, Rustum Y. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res. 2000;60:3717.PubMed

17.

Fischel JL, Formento P, Ciccolini J, et al. Mpact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracelular determinants of drug activity. Br J Cancer. 2002;86:1162–8.PubMedPubMedCentralCrossRef

18.

Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18–25.PubMedPubMedCentralCrossRef

19.

Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008;14:8–13.PubMedCrossRef

20.

Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2-deoxyuridine. Cancer Res. 1979;39:2406–13.PubMed

21.

Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487–9.PubMedCrossRef

22.

Polk A, Vaage-Nilsen M, Vistinsen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974–84.PubMedCrossRef

23.

Twelves CJ. Xeloda in adjuvant colon cancer therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 2006;6(4):278–87.PubMedCrossRef

24.

Hodi FS, Catalano P, Macdonald JS, et al. Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cáncer. Abstract presented at 2^nd International Conference on Gastrointestinal Oncology, Cologne, Germany, 1994.

25.

Walko CM, Lindley C. Capecitabine: a review. ClinTher. 2005;27(1):23–44.

26.

Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumour following oral administation to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–7.PubMedCrossRef

27.

Hiller SA, Zhuk RA, Lidak MY. Analogs of pyrimidine nucleosides. Dokl Adad Nauk. 1967;176:332–5.

28.

Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998;16(8):2877–85.PubMedCrossRef

29.

Saif MW, Syrigos KN, Katirzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18:335–48.PubMedCrossRef

30.

Kato T, Shimamoto Y, Uchida J, et al. Possible regulation of 5-fluorouracil-induced neuro and oral toxicities by two biochemical modulators consisting of S-1 a new oral formulation of 5-fluorouracil. Anticancer Res. 2001;21:1705–12.PubMed

31.

Heidelberger C, Boohar J, Kampschroer xx, et al. Fluorinated pyrimidines. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 nd 5-trifluoromethyl-2′-deoxyuridine-2-C-14. Cancer Res. 1965;25:377–381

32.

Temmink O, Emura T, De Bruin M, et al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98:779–89.PubMedCrossRef

33.

Suzuki N, Nakagawa F, Nukatsuka M, et al. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther MEd. 2011;2:393–7.PubMedPubMedCentral

34.

Peters G. Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids. 2014;33:358–74.PubMedCrossRef

35.

Emure T, Murakami Y, Nakagawa F, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13:545–9.

36.

Dexter D, Wolberg W, Ansfield F, et al. The clinical pharmacology of 5-trifluoromethyl-2′-deoxyuridine. Cancer Res. 1972;32:247–53.PubMed

37.

Emura T, Suzuki N, Fujioka A, et al. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thmidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol. 2005;27:449–55.PubMed

38.

Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–19.PubMedCrossRef

39.

Leichman L, Lenz HJ, Leichman CG, et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer. 1995;31A:1306–10.PubMedCrossRef

40.

Qui LX, Tang QY, Bai JL, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer. 2008;123:2384–9.CrossRef

41.

Longley DB, Boyer J, Allen WL, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res. 2002;62:2644–9.PubMed

42.

Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidiylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003;63:2898–904.PubMed

43.

Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epideimol Biomarkers Prev. 2000;9:1381–5.

44.

Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705–12.PubMed

45.

Aprile G, Mazzer M, Moroso S, et al. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anti-Cancer Drugs. 2009;20:217–29.PubMedCrossRef

46.

Jennings BA, Loke YK, Skinner J, et al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One. 2013;8(10):e78053.PubMedPubMedCentralCrossRef

47.

Muhale FA, Wetmore BA, Thomas RS, et al. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics. 2011;12:341–50.PubMedPubMedCentralCrossRef

48.

Sohn KJ, Croxford R, Yates Z, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004;96:134–44.PubMedCrossRef

49.

Zhang W, Press OA, Haiman CA, et al. Association of mehylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastastic colon cancer. J Clin Oncol. 2007;25:3726–31.PubMedCrossRef

50.

Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20(29):9775–827.PubMedPubMedCentralCrossRef

51.

Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol. 1995;6:871–81.PubMedCrossRef

52.

Jackman AL, Jodrell DI, Gibson W, et al. ICI D1694, an inhibitor of thymidylate synthase for clinical sutdy. AdvExp Med Biol. 1991;309A:19–23.CrossRef

53.

Jackman AL, Gibson W, Brown M, et al. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. SfbRcpMrfNiol. 1993;339:265–76.

54.

Price T, Wilson K, Simes RJ, et al. Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC Study. An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP). Paper presented at Annals Oncology, ESMO; Vienna, Austria; 2012

55.

Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013;49(10):2303–10.PubMedCrossRef

56.

Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991;9:827–31.PubMedCrossRef

57.

Zampino MG, Lorizzo K, Rocca A, et al. Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer. Anticancer Res. 2006;26:2425–8.PubMed

58.

Louvet C, de Gramont A. Pemetrexed in advanced colorectal cancer. Oncology (Williston Park). 2004;18(13):56–62.

59.

ClinicalTrials.gov NCT02588781

60.

Cao C, Kuang M, Xu W, et al. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Jpn Clin Oncol. 2015;25(12):1122–30.

61.

Shoji H, Morizane C, Sakamoto Y, et al. Phase I trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cáncer. Jpnj J ClinOncol. 2015; Epub ahead of print

62.

Ueno M, Okusaka T, Omuro Y, et al. A randomized phase II study plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Ann Oncol. 2015; Epub ahead of print

63.

Kobayakawa M, Kojima Y. Tegafur/gimeracil/oteracil (S-a) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoThargets. 2011;4:193–201.

64.

Yano W, Yokogaway T, Fukuoka M, et al. In vitro characterization of a novel dUTPase inhibitor, TAS-114 as a fluoropyrimidine enhancer. 24^th EORTC-NCI-AACR symposium 2012; Abstract 67

65.

ClinicalTrials.gov NCT01610479

66.

ClinicalTrials.gov NCT01489865

67.

ClinicalTrials.gov NCT01589419

68.

Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don’t know. JAMA. 1988;259(24):3571–8.PubMedCrossRef

69.

Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy colon carcinoma. N Engl J Med. 1990;322(6):352–8.PubMedCrossRef

70.

Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.PubMedCrossRef

71.

QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.CrossRef

72.

Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.PubMedCrossRef

73.

Andre T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study. J Clin Oncol. 2015. ePub ahead to print.

74.

Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059–64.PubMedCrossRef

75.

Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP-C07. J Clin Oncol. 2007;25:2198–2204

76.

Yothers G, MJ O’C, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.PubMedPubMedCentralCrossRef

77.

Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.PubMedCrossRef

78.

Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190–7.PubMedCrossRef

79.

Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.PubMedCrossRef

80.

Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol. 2007;25:102–9.PubMedCrossRef

81.

Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015; ePub ahead to print

82.

Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer. 2008;44(15):2201–11.CrossRef

83.

Yoshida M, Ishiguro M, Ikejiri K, et al. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;00:1–7.

84.

The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301–8.CrossRef

85.

Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–106.PubMedCrossRef

86.

Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001:2282–92.

87.

Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3617–27.PubMedCrossRef

88.

Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3605–16.PubMedCrossRef

89.

De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMedCrossRef

90.

Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metstatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRef

91.

Porschen R, Arkenau H-T, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217–23.PubMedCrossRef

92.

Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) as first-line treatment of metastaticcolorectal cancer: the GruppoOncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.PubMedCrossRef

93.

Cunningham D. Zalcberg Jr, Rath U, et al. final results of a randomised trial comparing tomudex (raltitrexed) with 4-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Ann Oncol. 1996;7(9):961–5.PubMedCrossRef

94.

Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus hig-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal Cancer Study Group. J Clin Oncol. 1998;16(9):2943–52.PubMedCrossRef

95.

Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (%-FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Paper presented at ASCO Meeting Abstract: Denver, USA: 1997

96.

Gravalos C, Salut A, Garcia-Giron C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. ClinTransl Oncol. 2012;14(8):606–12.

97.

Baba H, Muro K, Yasui H, et al. Updated results of the FIRIS study: a phase II/III trial of 5-FU/leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastastic colorectal cáncer (mCRC). J Clin Oncol. 2011;29(15):3562.CrossRef

98.

Otsuji T, Yamazaki K, Ojima H, et al. Updated survival of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastastic colorectal cancer (mCRC). J Clin Oncol. 2012;30(4):586.CrossRef

99.

Kim ST, Hong YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC. 2014;14:883.

100.

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef

101.

Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.PubMedCrossRef

102.

Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.PubMedCrossRef

103.

Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319–26.PubMedPubMedCentralCrossRef

104.

Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;204:1073–81.CrossRef

105.

Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization of Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.PubMedCrossRef

106.

Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT-I). Br J Cancer. 2010;102:1123–8.PubMedPubMedCentralCrossRef

107.

Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014;111:1726.1733.PubMedCentralCrossRef

108.

Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2009:CD006041

109.

Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579–88.PubMedCrossRef

110.

O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial T-04. J Clin Oncol. 2014;32:1927–34.

111.

MacDonald JS, Schein PS, Woolley PV, et al. 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Inern Med. 1980;93:533–6.CrossRef

112.

Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.PubMedCrossRef

113.

Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.PubMedCrossRef

114.

Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.PubMedCrossRef

115.

Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRef

116.

Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547–53.PubMedCrossRef

117.

Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastrern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270–5.PubMedCrossRef

118.

Hermann R, Bodoky G, Rushtaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–7.CrossRef

119.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRef

Titel: The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed
verfasst von: Jorge Hernando-Cubero
Ignacio Matos-García
Vicente Alonso-Orduña
Jaume Capdevila
Publikationsdatum: 10.04.2017
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2017
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9946-5

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Which Is Important: Incision Length or Oncological Outcome?

Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review

Adenocarcinoma of Gall Bladder Metastasis to Cervix: a Case Report with Review of Literature

BRUCE Protein, New Marker for Targeted Therapy of Gastric Carcinoma

Extramedullary Involvement of the Sigmoid Colon with Acute Lymphocytic Leukemia

Time to Progression of Pancreatic Cancer: Evaluation with Multi-Detector Computed Tomography

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie